Lurasidone

BreastfeedingGeriatricPediatric
  • TRADE NAME: Latuda (Sunovion)
  • INDICATIONS: Schizophrenia, depressive epidodes associated with bipolar I disorder
  • CLASS: Antipsychotic
  • HALF-LIFE: 18 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Alcohol, Amphetamines, CNS depressants, Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir, Dasatinib, Deferasirox, Diltiazem, Disopyramide, Dopamine, Dopamine agonists, Droperidol, Efavirenz, Epinephrine, Hydroxyzine, Ketoconazole, Levomepromazine, Lithium, MAO inhibitors, Methylphenidate, Metoclopramide, Ombitasvir/Paritaprevir/Ritonavir, Pimozide, Procainamide, Quinagolide, Quinidine, Rifampin, Strong CYP3A4 inducers or inhibitors, Tetrabenazine, Tocilizumab

PREGNANCY CATEGORY: B

INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

See full prescribing information for complete boxed warning.

Our database has 48 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
ENDOCRINE/METABOLIC
GENITOURINARY
RENAL
HEMATOLOGIC
OCULAR
OTHER


Page last updated 12/07/2017

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric